VAT1 Activators
VAT1 Activators are a diverse set of chemical compounds that, through various mechanisms, enhance the activity of VAT1, a protein implicated in cellular processes such as membrane fusion. Compounds such as Phorbol 12-myristate 13-acetate (PMA) and Diacylglycerol (DAG) act as activators of protein kinase C (PKC), which in turn may lead to the phosphorylation of proteins and pathways that interact with VAT1, thus potentially enhancing its activity. Forskolin, a direct stimulator of adenylate cyclase, raises cAMP levels, and along with cAMP analogs 8-Br-cAMP and 6-Bnz-cAMP, activates protein kinase A (PKA). The activation of PKA is known to result in phosphorylation events that can increase the activity of a variety of proteins, possibly including VAT1. Similarly, Ionomycin and A23187 (Calcimycin) both act to raise intracellular calcium levels, which may modulate calcium-dependent proteins and pathways to indirectly enhance VAT1's role in vesicle trafficking and membrane fusion.
The functional activityof VAT1 is further influenced by chemical compounds that affect cellular signaling in a more indirect manner. Epigallocatechin gallate (EGCG) and Bisindolylmaleimide I, through their modulatory effects on kinases and PKC, respectively, could lead to altered signaling environments that favor VAT1's membrane-associated activities. Sphingosine-1-phosphate (S1P), by activating intracellular signaling cascades via G protein-coupled receptors, also contributes to the potential enhancement of VAT1's role in membrane dynamics. The inhibition of protein phosphatases by Okadaic Acid induces a hyperphosphorylated state in cells that might increase VAT1-mediated activities by preventing the dephosphorylation of relevant signaling molecules. Thapsigargin, by disrupting calcium homeostasis through SERCA inhibition, can trigger a cascade of signaling events that could indirectly influence VAT1's activity. Collectively, these VAT1 activators, by targeting different signaling molecules and pathways, provide a multifaceted approach to enhancing the functional activity of VAT1 without directly increasing its expression or requiring direct binding to the protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased levels of cyclic AMP (cAMP) in cells. Elevated cAMP enhances protein kinase A (PKA) activity, which can phosphorylate various target proteins, including those involved in vesicle trafficking and membrane fusion processes. This PKA-mediated phosphorylation could enhance the functional activation of VAT1, a protein implicated in such cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, enzymes responsible for breaking down cAMP. By inhibiting these enzymes, IBMX increases intracellular cAMP levels, similarly activating PKA. The activation of PKA can subsequently lead to the phosphorylation and activation of proteins involved in vesicle trafficking, indirectly promoting VAT1 activity by modulating its cellular context. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, stimulating adenylate cyclase activity and raising intracellular cAMP levels. This cascade triggers PKA activation, which may phosphorylate proteins involved in membrane dynamics and vesicular transport. Such PKA-dependent phosphorylation processes could indirectly support VAT1 activation by optimizing its vesicle-associated functions. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, activates adenylate cyclase via β-adrenergic receptors, increasing cAMP levels and PKA activity. PKA can phosphorylate substrates that regulate vesicle trafficking and membrane fusion, potentially facilitating the activation of VAT1 by improving its functional environment in these processes. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels within cells. This elevation of cAMP enhances PKA activity, which may phosphorylate proteins involved in vesicle formation and transport. Through this mechanism, rolipram could indirectly activate VAT1 by influencing the cellular pathways it is involved in. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide selectively inhibits phosphodiesterase 3 (PDE3), causing an accumulation of cAMP in cells. This increase in cAMP levels stimulates PKA, which could phosphorylate and activate proteins involved in the regulation of vesicle trafficking. This mechanism may indirectly facilitate VAT1 activation by enhancing the processes it supports. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that directly activates PKA without the need for adenylate cyclase activation. By directly stimulating PKA, it may phosphorylate proteins involved in vesicular transport and membrane dynamics, potentially leading to the indirect activation of VAT1 by optimizing its functional engagement in these cellular processes. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its receptors, leading to an increase in intracellular cAMP levels via adenylate cyclase activation. This rise in cAMP promotes PKA activity, which could phosphorylate and thereby activate proteins associated with vesicle trafficking, indirectly supporting VAT1 activation through improved vesicular dynamics. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5 (PDE5), resulting in increased cAMP levels and enhanced PKA activity. This PKA-mediated phosphorylation could indirectly activate VAT1 by optimizing the cellular pathways involved in vesicle trafficking and membrane fusion, where VAT1 is functionally important. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, another β2-adrenergic agonist, stimulates adenylate cyclase to increase cAMP levels, activating PKA. This process may lead to the phosphorylation of proteins that regulate vesicular transport and membrane dynamics, indirectly promoting VAT1 activation by enhancing its functional context within these processes. | ||||||